# An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)

> **NCT00629564** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 60 (actual)

## Conditions studied

- GERD

## Interventions

- **DRUG:** Esomeprazole
- **DRUG:** Esomeprazole

## Key facts

- **NCT ID:** NCT00629564
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-09
- **Primary completion:** 2002-10
- **Final completion:** 2002-10
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2011-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00629564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00629564, "An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00629564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*